Advertisement
Canada markets open in 1 hour 55 minutes
  • S&P/TSX

    21,837.18
    -12.02 (-0.06%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • DOW

    38,790.43
    +75.63 (+0.20%)
     
  • CAD/USD

    0.7369
    -0.0020 (-0.27%)
     
  • CRUDE OIL

    82.71
    -0.01 (-0.01%)
     
  • Bitcoin CAD

    85,181.35
    -7,551.56 (-8.14%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,158.40
    -5.90 (-0.27%)
     
  • RUSSELL 2000

    2,024.74
    -14.58 (-0.72%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,128.25
    -103.25 (-0.57%)
     
  • VOLATILITY

    14.78
    +0.45 (+3.14%)
     
  • FTSE

    7,704.77
    -17.78 (-0.23%)
     
  • NIKKEI 225

    40,003.60
    +263.20 (+0.66%)
     
  • CAD/EUR

    0.6792
    0.0000 (0.00%)
     

Valeant CEO 'disappointed' in Allergan poison pill: CNBC

A sample of Botox is seen at the Long Island Plastic Surgical Group at the Americana Manhasset luxury shopping destination in Manhasset, New York September 30, 2010. REUTERS/Shannon Stapleton (Reuters)

(Reuters) - The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill. Allergan on Tuesday night said its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company. "We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday. (Reporting by Caroline Humer; Editing by Chizu Nomiyama)